FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2014169802> ?p ?o ?g. }

• W2014169802 endingPage "682" @default.
• W2014169802 startingPage "673" @default.
• W2014169802 abstract "Transurothelial drug delivery continues to be an attractive treatment option for a range of urological conditions; however, dosing regimens remain largely empirical. Recently, intravesical delivery of the nonsteroidal anti-inflammatory ketorolac has been shown to significantly reduce ureteral stent-related pain. While this latest development provides an opportunity for advancing the management of stent-related pain, clinical translation will undoubtedly require an understanding of the rate and extent of delivery of ketorolac into the bladder wall. Using an ex vivo porcine model, we evaluate the urothelial permeability and bladder wall distribution of ketorolac. The subsequent application of a pharmacokinetic (PK) model enables prediction of concentrations achieved in vivo. Ketorolac was applied to the urothelium and a transurothelial permeability coefficient (Kp) calculated. Relative drug distribution into the bladder wall after 90 min was determined. Ketorolac was able to permeate the urothelium (Kp = 2.63 × 10(-6) cm s(-1)), and after 90 min average concentrations of 400, 141 and 21 μg g(-1) were achieved in the urothelium, lamina propria and detrusor respectively. An average concentration of 87 μg g(-1) was achieved across the whole bladder wall. PK simulations (STELLA) were then carried out, using ex vivo values for Kp and muscle/saline partition coefficient (providing an estimation of vascular clearance), to predict 90 min in vivo ketorolac tissue concentrations. When dilution of the drug solution with urine and vascular clearance were taken into account, a reduced ketorolac concentration of 37 μg g(-1) across the whole bladder wall was predicted. These studies reveal crucial information about the urothelium's permeability to agents such as ketorolac and the concentrations achievable in the bladder wall. It would appear that levels of ketorolac delivered to the bladder wall intravesically would be sufficient to provide an anti-inflammatory effect. The combination of such ex vivo data and PK modeling provides an insight into the likelihood of achieving clinically relevant concentrations of drug following intravesical administration." @default.
• W2014169802 created "2016-06-24" @default.
• W2014169802 creator A5000076167 @default.
• W2014169802 creator A5031605242 @default.
• W2014169802 creator A5035301462 @default.
• W2014169802 creator A5037028264 @default.
• W2014169802 creator A5038131272 @default.
• W2014169802 creator A5038950965 @default.
• W2014169802 creator A5040758919 @default.
• W2014169802 creator A5078393403 @default.
• W2014169802 creator A5083839627 @default.
• W2014169802 date "2014-02-06" @default.
• W2014169802 modified "2023-09-26" @default.
• W2014169802 title "An ex Vivo Investigation into the Transurothelial Permeability and Bladder Wall Distribution of the Nonsteroidal Anti-Inflammatory Ketorolac" @default.
• W2014169802 cites W1513360523 @default.
• W2014169802 cites W1546333206 @default.
• W2014169802 cites W1968041658 @default.
• W2014169802 cites W1969888990 @default.
• W2014169802 cites W1995196918 @default.
• W2014169802 cites W2009180543 @default.
• W2014169802 cites W2013774345 @default.
• W2014169802 cites W2016220289 @default.
• W2014169802 cites W2016651596 @default.
• W2014169802 cites W2024392622 @default.
• W2014169802 cites W2033642835 @default.
• W2014169802 cites W2048938062 @default.
• W2014169802 cites W2049683045 @default.
• W2014169802 cites W2053432475 @default.
• W2014169802 cites W2058870872 @default.
• W2014169802 cites W2062557351 @default.
• W2014169802 cites W2064858753 @default.
• W2014169802 cites W2067417271 @default.
• W2014169802 cites W2070633823 @default.
• W2014169802 cites W2072209744 @default.
• W2014169802 cites W2073269610 @default.
• W2014169802 cites W2077492833 @default.
• W2014169802 cites W2080481898 @default.
• W2014169802 cites W2083093086 @default.
• W2014169802 cites W2086796015 @default.
• W2014169802 cites W2087848804 @default.
• W2014169802 cites W2089247139 @default.
• W2014169802 cites W2089999099 @default.
• W2014169802 cites W2099243020 @default.
• W2014169802 cites W2107807865 @default.
• W2014169802 cites W2137609666 @default.
• W2014169802 cites W2143608714 @default.
• W2014169802 cites W2147451560 @default.
• W2014169802 cites W2161441815 @default.
• W2014169802 cites W2193699731 @default.
• W2014169802 cites W2322239729 @default.
• W2014169802 cites W2397834018 @default.
• W2014169802 cites W2495991703 @default.
• W2014169802 cites W4246306438 @default.
• W2014169802 cites W4247365003 @default.
• W2014169802 cites W77754963 @default.
• W2014169802 cites W81324557 @default.
• W2014169802 doi "https://doi.org/10.1021/mp400274z" @default.
• W2014169802 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/24460452" @default.
• W2014169802 hasPublicationYear "2014" @default.
• W2014169802 type Work @default.
• W2014169802 sameAs 2014169802 @default.
• W2014169802 citedByCount "5" @default.
• W2014169802 countsByYear W20141698022015 @default.
• W2014169802 countsByYear W20141698022017 @default.
• W2014169802 countsByYear W20141698022018 @default.
• W2014169802 countsByYear W20141698022020 @default.
• W2014169802 countsByYear W20141698022023 @default.
• W2014169802 crossrefType "journal-article" @default.
• W2014169802 hasAuthorship W2014169802A5000076167 @default.
• W2014169802 hasAuthorship W2014169802A5031605242 @default.
• W2014169802 hasAuthorship W2014169802A5035301462 @default.
• W2014169802 hasAuthorship W2014169802A5037028264 @default.
• W2014169802 hasAuthorship W2014169802A5038131272 @default.
• W2014169802 hasAuthorship W2014169802A5038950965 @default.
• W2014169802 hasAuthorship W2014169802A5040758919 @default.
• W2014169802 hasAuthorship W2014169802A5078393403 @default.
• W2014169802 hasAuthorship W2014169802A5083839627 @default.
• W2014169802 hasBestOaLocation W20141698022 @default.
• W2014169802 hasConcept C126894567 @default.
• W2014169802 hasConcept C150903083 @default.
• W2014169802 hasConcept C178790620 @default.
• W2014169802 hasConcept C185592680 @default.
• W2014169802 hasConcept C207001950 @default.
• W2014169802 hasConcept C26291073 @default.
• W2014169802 hasConcept C2777540882 @default.
• W2014169802 hasConcept C2778446825 @default.
• W2014169802 hasConcept C2779762690 @default.
• W2014169802 hasConcept C2779820397 @default.
• W2014169802 hasConcept C2780820201 @default.
• W2014169802 hasConcept C71924100 @default.
• W2014169802 hasConcept C86803240 @default.
• W2014169802 hasConcept C98274493 @default.
• W2014169802 hasConceptScore W2014169802C126894567 @default.
• W2014169802 hasConceptScore W2014169802C150903083 @default.
• W2014169802 hasConceptScore W2014169802C178790620 @default.
• W2014169802 hasConceptScore W2014169802C185592680 @default.
• W2014169802 hasConceptScore W2014169802C207001950 @default.
• W2014169802 hasConceptScore W2014169802C26291073 @default.

• next